Arene Lifesciences - Due diligence report

A 360° intelligence report on Arene Lifesciences: trust score, financial health, credit view, compliance, directors, growth and distress sig…

2004-09-17 Sangareddy, Telangana Active Unlisted Active Compliant
Share
Connect MCP
AL Arene Lifesciences
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Arene Lifesciences — 360° Intelligence Report

Generated from MCA filings & public records
94/100
Trust Score
Low Risk

Arene Lifesciences is assessed as Low Risk with a Trust Score of 94/100. Arene Lifesciences is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 23 Sep 2026 from the latest processed filings. Arene Life Sciences Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
94/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Profitable - internal accruals available.
  • Externally credit-rated (B+).

Charges position: 6 open (122.40 cr) · 3 satisfied (36.94 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others4 48.0 cr
Karnataka Bank Ltd.2 48.0 cr
The Cosmos Co-Operative Bank Limited1 48.0 cr
The Cosmos Co - Op. Bank Ltd.1 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SATYANARAYANA REDDY KHAIRTABAD 01234567 Director 01/04/2018 6 yrs Approved
SANTOSH REDDY CHINNAMAIL 01234567 Director 01/04/2018 6 yrs Approved
KHAIRTABAD ANURAAG REDDY 01234567 Director 01/04/2018 6 yrs Approved
SATYANARAYANA REDDY CHINNAMAIL 01234567 Director 01/04/2018 6 yrs Approved
PRACHI GUPTA 01234567 Director 01/04/2018 6 yrs Approved
SATYANARAYANA REDDY CHINNAMAIL 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
S.r. Drugs And Intermediates Pvt.ltd.
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
S.r. Drugs And Intermediates Pvt.ltd. Holding Company 74.00%

Key managerial personnel: SATYANARAYANA REDDY KHAIRTABAD (Managing Director) · SATYANARAYANA REDDY CHINNAMAIL (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
6 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 6 open charge(s) of 122.40 cr already registered.
  • Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Sep 2024
Charge created
Others - 14.10 cr
10 Jun 2024
Director appointed
PRACHI GUPTA (Company Secretary)
08 Dec 2023
Charge created
Hdfc Bank Limited - 22.32 Lakh
31 Aug 2023
Charge created
Others - 20.00 cr
02 Sep 2022
Charge satisfied
Others
30 Dec 2021
Charge created
Karnataka Bank Ltd. - 8.90 cr
14 Sep 2020
Director ceased
NARAYAN SHIVA REDDY MORANGANTI
Director ceased
ROHITH
21 Apr 2020
Charge created
Karnataka Bank Ltd. - 47.50 cr
30 Sep 2019
Director ceased
SANTOSH REDDY CHINNAMAIL
Director ceased
KHAIRTABAD ANURAAG REDDY
06 Sep 2019
Director appointed
SANTOSH REDDY CHINNAMAIL (Director)
Director appointed
KHAIRTABAD ANURAAG REDDY (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Monarchcatalyst U24110MH1983PTC031365 Thane, Maharashtra, India
Universal Starch-Chem Allied L24110MH1973PLC016247 Mumbai, Maharashtra, India
Hpm India U15313DL1985PLC021149 Delhi, Delhi, India
Chryso U36992WB1950PTC018695 Hooghly, West Bengal, India
Arene Life Sciences (Unit 3) Private Limited U24239TG2006PTC049202 Hyderabad, Telangana, India
Gem Aromatics L24246MH1997PLC111057 Mumbai, Maharashtra, India
Aptar Pharma India Private Limited U29195MH1999PTC207807 Kalyan, Maharashtra, India
Bhimani Chemicals Private Limited U24114GJ2001PTC039432 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Arene Lifesciences before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Arene Lifesciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Arene Lifesciences - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 94/100, distress signals and MSME payment-delay disclosures - know whether Arene Lifesciences pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Arene Lifesciences - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Arene Lifesciences an active company?

Arene Lifesciences has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Arene Lifesciences financially healthy?

Arene Lifesciences has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Arene Lifesciences?

Its overall Trust Score is 94/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Arene Lifesciences?

The ultimate holding entity is S.r. Drugs And Intermediates Pvt.ltd.. 6 active director(s) are on record.

Does Arene Lifesciences have loans or charges against its assets?

6 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Arene Lifesciences up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Arene Lifesciences?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.